UY34983A - Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas - Google Patents

Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas

Info

Publication number
UY34983A
UY34983A UY34983A UY34983A UY34983A UY 34983 A UY34983 A UY 34983A UY 34983 A UY34983 A UY 34983A UY 34983 A UY34983 A UY 34983A UY 34983 A UY34983 A UY 34983A
Authority
UY
Uruguay
Prior art keywords
hcv
hepatitis
replication
inhibit
ompositions
Prior art date
Application number
UY34983A
Other languages
English (en)
Inventor
David A Degoey
Kevin R Woller
Lissa T Nelson
Sachin V Patel
Ryan G Keddy
Tammie K Jinkerson
Liu Dachun
John K Pratt
Jean C Califano
Charles W Hutchins
John T Randolph
Warren M Kati
David A Betebenner
Pamela L Donner
Allan C Krueger
Christopher E Motter
Mark A Matulenko
Douglas K Hutchinson
Charles A Flentge
Wagner Rolf
Clarence J Maring
Michael D Tufano
Todd W Rockway
Sarris Kathy
Seble H Wagaw
Daniel D Caspi
Mary E Bellizzi
Tami Pilot-Matias
Krishnan Preethi
Neeta C Mistry
Li Wenke
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43066241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Priority to UY34983A priority Critical patent/UY34983A/es
Publication of UY34983A publication Critical patent/UY34983A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/19—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/26—Polyhydroxylic alcohols containing only six-membered aromatic rings as cyclic part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Compuestos eficaces para inhibir la replicación del virus de la hepatitis C (?HCV?). Esta invención también se relaciona con procesos de elaboración de tales compuestos, con composiciones que compre nden a dichos compuestos y con métodos de uso de dichos para tratar una infección por HCV
UY34983A 2009-06-11 2013-08-21 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas UY34983A (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY34983A UY34983A (es) 2009-06-11 2013-08-21 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18629109P 2009-06-11 2009-06-11
US24283609P 2009-09-16 2009-09-16
US24359609P 2009-09-18 2009-09-18
UY32699A UY32699A (es) 2009-06-11 2010-06-10 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
UY34983A UY34983A (es) 2009-06-11 2013-08-21 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas

Publications (1)

Publication Number Publication Date
UY34983A true UY34983A (es) 2014-01-31

Family

ID=43066241

Family Applications (2)

Application Number Title Priority Date Filing Date
UY32699A UY32699A (es) 2009-06-11 2010-06-10 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados
UY34983A UY34983A (es) 2009-06-11 2013-08-21 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY32699A UY32699A (es) 2009-06-11 2010-06-10 Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv"), procesos, composiciones, y métodos relacionados

Country Status (40)

Country Link
US (5) US8691938B2 (es)
EP (5) EP2337781B1 (es)
JP (6) JP5530514B2 (es)
KR (2) KR101677481B1 (es)
CN (4) CN103819459B (es)
AR (3) AR077060A1 (es)
AU (1) AU2010258769C1 (es)
BR (1) BRPI1004894B8 (es)
CA (1) CA2737601C (es)
CL (2) CL2011000689A1 (es)
CO (1) CO6440538A2 (es)
CY (2) CY1114356T1 (es)
DK (3) DK2368890T3 (es)
DO (2) DOP2011000087A (es)
EA (3) EA023570B1 (es)
EC (3) ECSP11010937A (es)
ES (4) ES2565536T3 (es)
HK (4) HK1170739A1 (es)
HR (3) HRP20130671T1 (es)
HU (2) HUE028825T2 (es)
IL (4) IL211792A (es)
LT (1) LTC2368890I2 (es)
LU (1) LU92668I2 (es)
MX (2) MX2011005673A (es)
MY (1) MY186633A (es)
NL (1) NL300731I1 (es)
NO (1) NO2015012I1 (es)
NZ (1) NZ591973A (es)
PE (2) PE20110679A1 (es)
PH (1) PH12015500289A1 (es)
PL (3) PL2628481T3 (es)
PT (2) PT2368890E (es)
RS (3) RS53856B1 (es)
SG (2) SG171708A1 (es)
SI (2) SI2455376T1 (es)
TW (4) TW201519891A (es)
UA (1) UA118080C2 (es)
UY (2) UY32699A (es)
WO (1) WO2010144646A2 (es)
ZA (3) ZA201102425B (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110237636A1 (en) * 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
CA2761258C (en) 2009-05-13 2015-08-04 Gilead Sciences, Inc. Antiviral compounds
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CN103819459B (zh) * 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2767887A1 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
MX2012010252A (es) 2010-03-04 2013-02-01 Enanta Pharm Inc Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv).
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
AU2014200725B2 (en) * 2010-06-10 2016-05-12 Abbvie Ireland Unlimited Company Solid compositions
PE20130395A1 (es) 2010-06-24 2013-04-10 Gilead Sciences Inc Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
MY164064A (en) * 2010-10-13 2017-11-15 Abbvie Bahamas Ltd Anti-viral compounds
AU2016238925B2 (en) * 2010-10-13 2018-12-20 Abbvie Ireland Unlimited Company Anti-viral compounds
KR102095698B1 (ko) 2010-10-29 2020-04-01 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012083048A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
CA2819894A1 (en) * 2010-12-16 2012-06-21 Abbvie Inc. Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709455A4 (en) 2011-05-18 2014-11-05 Enanta Pharm Inc PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
US20150126747A1 (en) * 2011-05-26 2015-05-07 Abbvie Inc. Anti-viral compounds
US20150105548A1 (en) * 2011-05-26 2015-04-16 Abbvie Inc Anti-viral compounds
ME03009B (me) 2011-09-16 2018-10-20 Gilead Pharmasset Llc Metode za lecenje hcv-a
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2015100285B4 (en) * 2011-10-21 2015-06-11 Abbvie Ireland Unlimited Company Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104383541A (zh) * 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
ES2572355B1 (es) * 2011-10-21 2017-08-24 Abbvie Inc. Combinación de aad para uso en el tratamiento del vhc
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
EP2602248A1 (en) * 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
US8946238B2 (en) 2011-12-22 2015-02-03 Gilead Sciences, Inc. Pyrazolo[1,5-A]pyrimidines as antiviral agents
WO2013101552A1 (en) 2011-12-28 2013-07-04 Abbvie Inc. Methods for treating hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
CA2857339C (en) * 2011-12-29 2015-11-17 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9326973B2 (en) * 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR102181318B1 (ko) 2012-04-17 2020-11-20 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 화합물 및 방법
WO2014004674A2 (en) 2012-06-27 2014-01-03 Abbvie Inc. Methods for treating hcv
AU2013318309A1 (en) 2012-09-18 2015-04-02 Abbvie Inc. Methods for treating hepatitis C
RU2015114566A (ru) * 2012-09-18 2016-11-10 Эббви Инк. Способы лечения гепатита с
JP2015508418A (ja) 2013-01-31 2015-03-19 ギリアド ファーマセット エルエルシー ２種の抗ウイルス化合物のコンビナトリアル製剤
CN109908353A (zh) * 2013-03-14 2019-06-21 艾伯维公司 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015002952A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
HRP20220911T1 (hr) 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3099295A1 (en) 2014-01-28 2016-12-07 Abbvie Inc. Dose adjustment in combination therapy of hepatitis c
KR20160133004A (ko) 2014-04-04 2016-11-21 엑스-알엑스, 인크. 오토탁신의 치환된 스피로시클릭 억제제
CN104030959B (zh) * 2014-06-24 2016-08-24 苏州东南药业股份有限公司 一种氘代的丙型肝炎病毒抑制剂
WO2016040588A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Treatment of hcv by administering four different anti-hcv compounds with food
CN104402776B (zh) * 2014-12-05 2017-06-13 中国石油天然气股份有限公司 一种二元醇磺酸酯化合物及其制备方法与应用
WO2016134053A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134051A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134057A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
WO2016134050A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
WO2016134056A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
KR102637828B1 (ko) * 2015-06-26 2024-02-20 애브비 인코포레이티드 Hcv의 치료를 위한 고형 약제학적 조성물
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
CN105294828B (zh) * 2015-11-11 2018-09-04 苏州明锐医药科技有限公司 奥贝他韦的制备方法
TW201718608A (zh) * 2015-11-23 2017-06-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd 用於抗ｃ型肝炎病毒感染的含矽化合物
SG11201808220VA (en) 2016-03-22 2018-10-30 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MX2018013178A (es) 2016-04-28 2019-06-24 Abbvie Inc Polimorfos cristalinos de ombitasvir.
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
CN110382487B (zh) * 2017-03-22 2021-04-02 正大天晴药业集团股份有限公司 用于抗丙型肝炎病毒感染的含硅化合物
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
GB201706806D0 (en) * 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
CN107474105B (zh) * 2017-08-01 2021-08-31 安徽拜善晟制药有限公司 一种原料药奥比他韦的制备方法
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
EA202091835A1 (ru) 2018-01-31 2020-10-20 Янссен Сайенсиз Айрлэнд Анлимитед Компани Замещенные циклоалкилом пиразолопиримидины, обладающие активностью против rsv
IL300572A (en) 2018-02-13 2023-04-01 Gilead Sciences Inc PD–1/PD–L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
ES2957316T3 (es) 2018-04-23 2024-01-17 Janssen Sciences Ireland Unlimited Co Compuestos heteroaromáticos que tienen actividad contra VSR
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN115298173A (zh) * 2020-03-31 2022-11-04 田边三菱制药株式会社 羟基吡咯烷衍生物及其医药用途
WO2021236475A1 (en) * 2020-05-18 2021-11-25 Asinex Corporation Compounds that inhibit asparagine synthetase and their methods of use
WO2022246109A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
CN115594591A (zh) * 2021-06-28 2023-01-13 凯特立斯（深圳）科技有限公司（Cn） 一种催化不对称氢化制备哌仑他韦中间体的方法
CN114656389B (zh) * 2022-04-27 2023-12-15 河南大学 一种1-苯基吡咯烷的合成方法

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE75755C (de) 1894-06-14 DAHL & COMP, in Barmen Verfahren zur Darstellung von aromatisch substituirten Amidodinaphtylmethanen.
US3225061A (en) * 1962-10-17 1965-12-21 Nat Distillers Chem Corp Derivatives of 2,5-diarylpyrrole
JPS62195307A (ja) * 1986-02-24 1987-08-28 Kumiai Chem Ind Co Ltd 農園芸用殺菌剤
EP0701446A4 (en) 1993-05-24 1997-04-23 Smithkline Beecham Corp HEMOREGULATORS PEPTIDES
US5683999A (en) * 1995-03-17 1997-11-04 The Dupont Merck Pharmaceutical Company Cyclic urea HIV protease inhibitors
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JPH09255949A (ja) * 1996-03-21 1997-09-30 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子
US5935982A (en) * 1997-02-28 1999-08-10 The University Of North Carolina At Chapel Hill Methods of treating retroviral infection and compounds useful therefor
US6235493B1 (en) * 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6369091B1 (en) * 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
ATE292465T1 (de) 1998-05-22 2005-04-15 Avanir Pharmaceuticals Benzimidazol-derivate als ige-modulatoren
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
JP3968933B2 (ja) * 1998-12-25 2007-08-29 コニカミノルタホールディングス株式会社 エレクトロルミネッセンス素子
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
CA2405521C (en) * 2000-04-05 2010-06-29 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7065453B1 (en) 2000-06-15 2006-06-20 Accelrys Software, Inc. Molecular docking technique for screening of combinatorial libraries
ES2281434T3 (es) 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
US6388093B1 (en) 2001-01-05 2002-05-14 Sun Chemical Corporation Syntheses for preparing 1,4-diketopyrrolo [3,4-c]pyrroles
CN100509797C (zh) 2001-06-11 2009-07-08 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
RU2286343C2 (ru) 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
AU2003216274A1 (en) * 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
JP3925265B2 (ja) * 2002-03-25 2007-06-06 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及びそれを用いた表示装置
MXPA04012642A (es) 2002-06-14 2005-03-23 Merck & Co Inc Inhibidores de la cinesina mitotica.
WO2004005283A1 (en) 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
KR100482276B1 (ko) * 2002-08-12 2005-04-13 한국과학기술연구원 피롤계 화합물, 그 중합체 및 이들을 이용한 ｅｌ 소자
US20050069522A1 (en) 2002-08-12 2005-03-31 Richard Colonno Combination pharmaceutical agents as inhibitors of HCV replication
GB0229518D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7544192B2 (en) * 2003-03-14 2009-06-09 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
RU2006118359A (ru) * 2003-10-27 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Комбинации для лечения вирусного гепатита с (hcv)
DK1718608T3 (da) * 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
BRPI0401908A (pt) 2004-06-04 2006-01-17 Univ Rio De Janeiro Compostos inibidores de serina protease, processo de obtenção e uso para tratamento de flaviviroses
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP5014129B2 (ja) 2004-07-27 2012-08-29 ギリアード サイエンシーズ， インコーポレイテッド イミダゾ［４，５−ｄ］ピリミジン、それらの使用および調製方法
AU2005272619A1 (en) 2004-08-13 2006-02-23 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
EP1844035A1 (en) 2005-02-01 2007-10-17 Wyeth Amino-pyridines as inhibitors of beta-secretase
BRPI0606902A2 (pt) 2005-02-14 2009-07-28 Wyeth Corp composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
US7894996B2 (en) 2005-02-28 2011-02-22 The Rockefeller University Structure of the hepatitis C NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2006261132A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
US7541359B2 (en) 2005-06-30 2009-06-02 Janssen Pharmaceutica N.V. N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
JP2009501217A (ja) 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
RU2008128452A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
RU2008128453A (ru) 2005-12-12 2010-01-20 Дженелабс Текнолоджис, Инк. (Us) Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
JP2009521479A (ja) 2005-12-21 2009-06-04 アボット・ラボラトリーズ 抗ウイルス化合物
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
US7763731B2 (en) * 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
CA2634699A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
WO2007082554A1 (en) 2006-01-23 2007-07-26 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Modulators of hcv replication
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics Inc composto de ligação de domìnio bir da iap
JP2007320925A (ja) * 2006-06-02 2007-12-13 Mitsubishi Chemicals Corp トリアリールアミン系化合物並びにそれを用いた電子写真感光体及び画像形成装置
EA015127B1 (ru) 2006-06-08 2011-06-30 Эли Лилли Энд Компани Антагонисты мсн-рецепторов
BRPI0713025A2 (pt) 2006-06-16 2012-04-17 Syngenta Participations Ag compostos derivados de etenila carboxamida úteis como microbiocidas, método de controle ou prevenção de infestação de plantas úteis por microorganismo fitopatogênicos e composição para controle e prevenção dos referidos microorganismos
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7745636B2 (en) * 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2097405A2 (en) * 2006-11-21 2009-09-09 Smithkline Beecham Corporation Anti-viral compounds
WO2008064218A2 (en) 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008074450A2 (en) 2006-12-20 2008-06-26 Nicox S.A. Non-peptidic renin inhibitors nitroderivatives
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
NZ580313A (en) 2007-04-12 2011-11-25 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents
CN110724124A (zh) * 2007-05-17 2020-01-24 株式会社半导体能源研究所 三唑衍生物
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009003009A1 (en) 2007-06-26 2008-12-31 Enanta Pharmaceuticals, Inc. Substituted pyrrolidine as anti-infectives
JP2010535711A (ja) 2007-08-03 2010-11-25 シェーリング コーポレイション 複素環式置換ピペラジンを用いる、ｃｘｃｒ３媒介性疾患の処置方法
US7728027B2 (en) * 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
JP2011511841A (ja) 2008-02-12 2011-04-14 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0822323A2 (pt) 2008-02-13 2015-06-16 Bristol Myers Squibb Co Imidazolil bifenil imidazóis como inibidores do vírus da hepatite c
EP2444070A1 (en) 2008-02-28 2012-04-25 Abbott Laboratories Tablets
JP2009246097A (ja) * 2008-03-31 2009-10-22 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子、表示装置、及び照明装置
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2009143361A1 (en) 2008-05-22 2009-11-26 Smithkline Beecham Corporation Amido anti-viral compounds
WO2009155709A1 (en) 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
ES2392611T3 (es) * 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
WO2010015090A1 (en) 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) * 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010059858A1 (en) 2008-11-19 2010-05-27 Duke University Manassantin compounds and methods of making and using same
JP2010126571A (ja) 2008-11-26 2010-06-10 Toyo Ink Mfg Co Ltd 有機エレクトロルミネッセンス素子材料および有機エレクトロルミネッセンス素子
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
NZ593806A (en) 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
CN104163816A (zh) 2008-12-03 2014-11-26 普雷西迪奥制药公司 Hcv ns5a的抑制剂
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
MX2011006333A (es) * 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
US8314135B2 (en) * 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8637561B2 (en) * 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8394968B2 (en) * 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8420686B2 (en) * 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) * 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
UY32462A (es) * 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
KR20130130875A (ko) 2009-02-27 2013-12-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8426458B2 (en) * 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) * 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102427729B (zh) 2009-03-27 2014-09-03 默沙东公司 丙型肝炎病毒复制的抑制剂
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
BRPI1012282A2 (pt) 2009-03-27 2015-09-22 Presidio Pharmaceuticals Inc inibidores de anel fundidos da hepatite c.
US20110237636A1 (en) * 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120022879A (ko) 2009-04-08 2012-03-12 바스프 에스이 피롤로피롤 유도체, 그의 제조법 및 반도체로서의 용도
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2419404B1 (en) * 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
US8436036B2 (en) 2009-04-24 2013-05-07 Janssen R&D Ireland Diaryl ethers
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
CA2761258C (en) * 2009-05-13 2015-08-04 Gilead Sciences, Inc. Antiviral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012528194A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの整列型アリール部分で構成された抗菌性化合物
WO2010138791A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CN103819459B (zh) 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) * 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8609648B2 (en) * 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) * 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
CA2767887A1 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
EP2462135A1 (en) 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
AU2010291215A1 (en) 2009-09-03 2012-02-23 Janssen Sciences Ireland Uc Bis-benzimidazole derivatives
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) * 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475254A4 (en) 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CA2781140C (en) * 2009-12-04 2017-10-24 National Health Research Institutes Proline derivatives for use to treat hepatitis c infection
US8653070B2 (en) * 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2784748A1 (en) * 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MX2012007420A (es) 2009-12-24 2012-07-23 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones de flavivirus.
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
BR112012018529A2 (pt) 2010-01-25 2016-08-09 Enanta Pharm Inc inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
EP2528926A4 (en) 2010-01-28 2013-06-19 Boehringer Ingelheim Int HEPATITIS C INHIBITOR COMPOUNDS
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
MX2012010252A (es) * 2010-03-04 2013-02-01 Enanta Pharm Inc Agentes farmaceuticos en combinacion como inhibidores de la replicacion del virus de hepatitis c (hcv).
AU2011224698A1 (en) * 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2550268A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2575475A4 (en) 2010-05-28 2013-11-27 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
US8778938B2 (en) * 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CA2802067A1 (en) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
JP5619289B2 (ja) 2010-09-24 2014-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN102420414A (zh) * 2010-09-27 2012-04-18 通领科技集团有限公司 高灵敏度泄漏电流检测断路器
US20130280214A1 (en) 2010-09-29 2013-10-24 Merck Sharp & Dohme Corp. Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
KR20140001879A (ko) 2010-09-29 2014-01-07 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
EP2621932A4 (en) 2010-09-29 2014-03-26 Merck Sharp & Dohme TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
ES2548286T3 (es) 2010-11-04 2015-10-15 Theravance Biopharma R&D Ip, Llc Nuevos inhibidores del virus de la hepatitis C
KR20200140924A (ko) 2010-11-17 2020-12-16 길리애드 파마셋 엘엘씨 항바이러스 화합물
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
CY2015012I2 (el) 2016-04-13
WO2010144646A3 (en) 2011-03-17
WO2010144646A2 (en) 2010-12-16
DK2628481T3 (en) 2016-06-06
NO2015012I2 (no) 2015-04-22
EP2368890B9 (en) 2013-10-30
US8691938B2 (en) 2014-04-08
EA023570B1 (ru) 2016-06-30
EP2337781B1 (en) 2014-07-23
IL233857A0 (en) 2014-09-30
IL229248A (en) 2014-06-30
SI2628481T1 (sl) 2016-08-31
PH12015500289B1 (en) 2015-09-07
LU92668I2 (fr) 2016-03-31
UA118080C2 (uk) 2018-11-26
KR101452916B1 (ko) 2014-10-24
JP2012529534A (ja) 2012-11-22
EP2337781A2 (en) 2011-06-29
AR077060A1 (es) 2011-07-27
CN102333772A (zh) 2012-01-25
ECSP17064986A (es) 2017-10-31
JP6559736B2 (ja) 2019-08-14
EP2455376A1 (en) 2012-05-23
CN103172620A (zh) 2013-06-26
ES2414934T9 (es) 2013-11-28
JP5911838B2 (ja) 2016-04-27
EP2368890A1 (en) 2011-09-28
ZA201203502B (en) 2013-01-30
CN103819459A (zh) 2014-05-28
IL211792A0 (en) 2011-06-30
HUS1500019I1 (hu) 2015-05-28
HK1170739A1 (en) 2013-03-08
EA201170401A1 (ru) 2011-10-31
IL233857A (en) 2016-05-31
EP2853531A2 (en) 2015-04-01
BRPI1004894A2 (pt) 2018-05-15
US20100317568A1 (en) 2010-12-16
EA020031B1 (ru) 2014-08-29
HK1152620A1 (en) 2012-02-17
HK1161245A1 (en) 2012-08-24
ECSP13010937A (es) 2013-10-31
CN102333772B (zh) 2013-12-11
AU2010258769A1 (en) 2010-12-16
HRP20160408T1 (hr) 2016-05-20
KR20120117620A (ko) 2012-10-24
BRPI1004894A8 (pt) 2021-03-16
CN103819459B (zh) 2017-05-17
KR101677481B1 (ko) 2016-11-18
RS53856B1 (en) 2015-08-31
PL2455376T3 (pl) 2015-06-30
IL234781A (en) 2016-07-31
JP2014144973A (ja) 2014-08-14
KR20140037974A (ko) 2014-03-27
IL211792A (en) 2014-09-30
CL2013002299A1 (es) 2013-11-08
CA2737601C (en) 2014-10-21
DK2455376T3 (en) 2015-03-02
CN103819537A (zh) 2014-05-28
AU2010258769C1 (en) 2016-04-28
NL300731I2 (es) 2016-01-07
BRPI1004894B1 (pt) 2021-03-23
PT2455376E (pt) 2015-03-04
AU2010258769B2 (en) 2012-08-23
LTC2368890I2 (lt) 2017-03-10
EA201300495A1 (ru) 2013-09-30
EP2455376B1 (en) 2014-11-26
IL229248A0 (en) 2013-12-31
JP2016128456A (ja) 2016-07-14
NZ591973A (en) 2013-03-28
TW201347759A (zh) 2013-12-01
BRPI1004894B8 (pt) 2021-05-25
UY32699A (es) 2010-12-31
DK2368890T3 (da) 2013-07-22
CO6440538A2 (es) 2012-05-15
MX339989B (es) 2016-06-21
PE20141083A1 (es) 2014-10-03
SG10201702522UA (en) 2017-05-30
PT2368890E (pt) 2013-07-17
AR092505A2 (es) 2015-04-22
PL2368890T3 (pl) 2013-10-31
US9006387B2 (en) 2015-04-14
JP2019194254A (ja) 2019-11-07
HUE028825T2 (en) 2017-01-30
ES2526908T3 (es) 2015-01-16
PE20110679A1 (es) 2011-10-20
TW201519891A (zh) 2015-06-01
PL2628481T3 (pl) 2016-08-31
TW201102063A (en) 2011-01-16
CN103172620B (zh) 2014-10-29
EP2368890B1 (en) 2013-04-17
EA026848B1 (ru) 2017-05-31
ES2565536T3 (es) 2016-04-05
DOP2011000087A (es) 2018-02-28
TWI402070B (zh) 2013-07-21
HK1186415A1 (zh) 2014-03-14
MX2011005673A (es) 2011-06-20
NL300731I1 (es) 2016-01-07
RS52854B (en) 2013-12-31
CL2011000689A1 (es) 2011-11-11
DOP2013000185A (es) 2013-09-30
TW201334778A (zh) 2013-09-01
HRP20130671T1 (en) 2013-10-11
ZA201203503B (en) 2014-01-29
SI2455376T1 (sl) 2015-03-31
EP2853531A3 (en) 2015-08-12
EA201400115A1 (ru) 2014-08-29
JP2017171680A (ja) 2017-09-28
ES2511440T3 (es) 2014-10-22
US20140315792A1 (en) 2014-10-23
JP5530514B2 (ja) 2014-06-25
JP2014065710A (ja) 2014-04-17
EP2628481B1 (en) 2016-02-24
SG171708A1 (en) 2011-07-28
US20110207699A1 (en) 2011-08-25
RS54790B1 (sr) 2016-10-31
CY1114356T1 (el) 2016-04-13
US20110092415A1 (en) 2011-04-21
ZA201102425B (en) 2012-09-26
US8921514B2 (en) 2014-12-30
PH12015500289A1 (en) 2015-09-07
JP6159830B2 (ja) 2017-07-05
HRP20150017T1 (hr) 2015-04-24
EP2628481A1 (en) 2013-08-21
ES2414934T3 (es) 2013-07-23
US20150218194A1 (en) 2015-08-06
TWI469780B (zh) 2015-01-21
CY2015012I1 (el) 2016-04-13
ECSP11010937A (es) 2011-05-31
CA2737601A1 (en) 2010-12-16
JP5922699B2 (ja) 2016-05-24
EA201170401A8 (ru) 2014-03-31
MY186633A (en) 2021-07-31
NO2015012I1 (no) 2015-05-04
AR094816A2 (es) 2015-08-26
TWI486159B (zh) 2015-06-01

Similar Documents

Publication Publication Date Title
UY34983A (es) Compuestos antivirales eficaces para inhibir la replicación del virus de la hepatitis c ("hcv") y c omposiciones relacionadas
CO6761348A2 (es) Compuestos antivirales
CL2012000573A1 (es) Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv.
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CL2014000612A1 (es) Compuestos derivados de prolinas macrociclicas, inhibidores de las proteasas de serina del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y su uso para tratar una infeccion viral tal como la infeccion por el virus de la hepatitis c (vhc).
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
EA201270423A1 (ru) Ингибиторы протеазы hcv
CO6390076A2 (es) Inhibidores de hcv ns5a
CO6390077A2 (es) Inhibidores de hacv ns5a
CL2008002995A1 (es) Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih.
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2011002494A1 (es) Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih).
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CL2016000300A1 (es) Métodos terapéuticos
BR112014013972A8 (pt) inibidores de hcv nssa
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
CL2008003045A1 (es) Compuestos derivados de dioxolano timina fosforamidatos; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de infecciones virales, tales como el vih

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210426